宜明昂科-B(01541):IMM0306治疗系统性红斑狼疮 (SLE)的Ib期临床试验成功完成首例患者给药

智通财经
24 Oct 2024

智通财经APP讯,宜明昂科-B(01541)公布,IMM0306治疗系统性红斑狼疮 (SLE)的Ib期临床试验成功完成首例患者给药。

据悉,由该集团独立研发的IMM0306是一种靶向分化簇47 (CD47)及分化簇20 (CD20) 的双特异性分子,是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。通过增强的抗体依赖的细胞吞噬作用(ADCP)和抗体依赖的细胞毒性作用 (ADCC),IMM0306可同时与恶性B细胞上表达的CD47和CD20结合,相较于对 CD47,对CD20的亲和力更高,从而可改善治疗效果。

截至本公告日期,该集团拥有IMM0306的全球知识产权及商业化权利。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10